ARK Investment Management Increases NTLA Holdings
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy NTLA?
Source: stocktwits
- Consistent NTLA Accumulation: ARK Investment Management has steadily increased its holdings in Intellia Therapeutics (NTLA) throughout 2026, acquiring over 263,848 shares from January to April, with a potential investment exceeding $3.5 million, reflecting a strong long-term confidence in the biotech firm.
- Positive Clinical Trial Results: Intellia recently reported positive Phase 3 trial results for lonvoculin ziclumeran (lonvo-z) for hereditary angioedema treatment and has initiated a rolling Biologics License Application submission to the FDA, aiming for a potential U.S. launch in the first half of 2027.
- Rocket Lab Stock Sale: ARK's second sale of Rocket Lab (RKLB) stock this month involved offloading 50,312 shares, potentially worth over $4 million, indicating a strategy to lock in gains after RKLB's impressive 262% rise over the past year.
- Retail Investor Sentiment: On Stocktwits, retail sentiment for NTLA is in the 'extremely bullish' territory, while RKLB is 'bullish', suggesting positive market expectations for both stocks, despite ARKK and ARKQ showing 'bearish' sentiment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NTLA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NTLA
Wall Street analysts forecast NTLA stock price to rise
22 Analyst Rating
9 Buy
12 Hold
1 Sell
Moderate Buy
Current: 13.630
Low
4.00
Averages
16.50
High
54.00
Current: 13.630
Low
4.00
Averages
16.50
High
54.00
About NTLA
Intellia Therapeutics, Inc. is a clinical-stage gene editing company focused on developing medicine with CRISPR-based therapies and other core technologies. CRISPR/Cas9 is a gene editing technology that leverages the body’s natural processes to precisely edit DNA. The Company is developing lonvoguran ziclumeran (lonvo-z), referred to as NTLA-2002, for the treatment of hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z) also referred to as NTLA-2001, for the treatment of transthyretin (ATTR) amyloidosis. It is focused on completing late-stage clinical development of its lead product candidates, lonvo-z for the treatment of patients with HAE and nex-z for the treatment of patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM) and hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). Its lead product candidates are the first in vivo genome editing product candidates into Phase III development. Its other pipeline products include REGV131-LNP1265 and AVC-201 & AVC-203.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Intellia Initiates BLA Submission for Lonvo-z in HAE Treatment
- BLA Submission Initiated: Intellia Therapeutics has begun the rolling submission of a Biologics License Application (BLA) to the FDA for lonvo-z, aimed at providing a one-time treatment for hereditary angioedema (HAE), which, if approved, would be the world's first CRISPR-based gene editing therapy.
- Clinical Trial Success: The Phase 3 HAELO trial of lonvo-z met its primary and all key secondary endpoints, demonstrating that most patients experienced freedom from HAE attacks and ongoing therapy needs during the six-month observation period, indicating its potential revolutionary impact on treatment.
- Expedited Review Pathway: With the FDA granting lonvo-z the Regenerative Medicine Advanced Therapy (RMAT) designation, Intellia can submit portions of the BLA on an ongoing basis, anticipating completion in the second half of 2026, and if approved, plans to commercially launch in the first half of 2027, significantly enhancing patient access to treatment.
- Regulatory Designations: Lonvo-z has received five notable regulatory designations, including Orphan Drug and RMAT designations from the FDA, highlighting its potential in treating HAE and the possibility of improving patients' quality of life while reducing reliance on long-term therapies.
See More
ARK Investment Management Increases NTLA Holdings
- Consistent NTLA Accumulation: ARK Investment Management has steadily increased its holdings in Intellia Therapeutics (NTLA) throughout 2026, acquiring over 263,848 shares from January to April, with a potential investment exceeding $3.5 million, reflecting a strong long-term confidence in the biotech firm.
- Positive Clinical Trial Results: Intellia recently reported positive Phase 3 trial results for lonvoculin ziclumeran (lonvo-z) for hereditary angioedema treatment and has initiated a rolling Biologics License Application submission to the FDA, aiming for a potential U.S. launch in the first half of 2027.
- Rocket Lab Stock Sale: ARK's second sale of Rocket Lab (RKLB) stock this month involved offloading 50,312 shares, potentially worth over $4 million, indicating a strategy to lock in gains after RKLB's impressive 262% rise over the past year.
- Retail Investor Sentiment: On Stocktwits, retail sentiment for NTLA is in the 'extremely bullish' territory, while RKLB is 'bullish', suggesting positive market expectations for both stocks, despite ARKK and ARKQ showing 'bearish' sentiment.
See More
Intellia Reports Positive Phase 3 Results for Lonvo-z in Hereditary Angioedema
- Clinical Trial Success: Intellia Therapeutics reported positive Phase 3 results from its global HAELO trial, demonstrating that a single dose of lonvoguran ziclumeran achieved an 87% reduction in swelling attacks, marking a significant milestone for gene-editing treatments.
- Significant Patient Response: Among 80 participants, those receiving lonvo-z had a mean monthly attack rate of 0.26 compared to 2.10 in the placebo group, showcasing a clear advantage in attack frequency reduction, with 62% of patients attack-free and off ongoing medication.
- Favorable Safety Profile: Lonvo-z was generally well tolerated, with all reported adverse events being mild or moderate, and no serious adverse events occurred, indicating a strong safety profile that supports future market adoption.
- Regulatory Progress: Intellia has initiated a rolling BLA submission to the FDA for lonvo-z, expected to be completed in the second half of 2026; if approved, it could become the first in vivo CRISPR-based therapy on the market, with a potential U.S. launch targeted for 2027.
See More
Intellia Therapeutics Launches $150M Public Offering
- Offering Announcement: Intellia Therapeutics has initiated a public offering of $150 million in common stock, aimed at funding future research and operations, thereby strengthening its market position in gene therapy.
- Underwriter Option: The company may grant underwriters a 30-day option to purchase an additional 15% of shares, a flexible financing strategy that will help meet market demand and optimize its capital structure.
- Clinical Progress: Following the FDA lifting the clinical hold on nex-z, Intellia's stock surged, reflecting market confidence in its product pipeline, particularly in the ATTR-CM space where potential breakthroughs are anticipated.
- Future Plans: Intellia is set to launch Lonvoguran Ziclumeran in 2026, and with ongoing clinical advancements, the company's market outlook in hereditary angioedema treatment is becoming increasingly promising.
See More
NASDAQ 100 Pre-Market Activity Overview
- Market Performance: The NASDAQ 100 Pre-Market Indicator is down 22.14 points to 27,281.53, indicating cautious market sentiment that may influence short-term investor decisions.
- Active Stocks: Organon & Co. (OGN) rises by $1.91 to $13.17 with a trading volume of 34,420,118 shares, currently priced at 146.33% of its target price, reflecting optimistic market expectations for its future performance.
- Earnings Forecast: Intel Corporation (INTC) has had three upward revisions in earnings forecasts over the past four weeks, with a current stock price of $82.86 and an expected EPS of $0.08 for the fiscal quarter ending June 2027, showcasing market confidence in its future profitability.
- Short Interest Data: Sagimet Biosciences Inc. (SGMT) and Intellia Therapeutics, Inc. (NTLA) have days to cover of 10.41 and 15.42 respectively, indicating high short-term trading activity for these stocks, which may impact their price volatility.
See More
Intellia Achieves Breakthrough in Rare Genetic Condition Treatment
- Clinical Trial Success: Intellia Therapeutics' lonvo-z demonstrated a remarkable efficacy in its Phase 3 trial, with 62% of patients completely free of HAE attacks over six months, compared to just 11% in the placebo group, indicating a potential paradigm shift in treatment for this rare genetic condition.
- FDA Application Initiated: The company has commenced a rolling Biologics License Application submission to the U.S. FDA, with plans for a potential U.S. launch of lonvo-z in the first half of 2027, which could open significant market opportunities and revenue streams for Intellia.
- Positive Market Reaction: Intellia's shares surged over 9% in pre-market trading on Monday, making it the top trending stock, reflecting strong investor optimism about lonvo-z, with a year-to-date increase of 52% in stock price.
- Significant Patient Impact: As a one-time treatment, lonvo-z aims to permanently reduce kallikrein and bradykinin levels through CRISPR gene editing, offering new hope for patients who have long suffered from HAE, potentially improving their quality of life significantly.
See More
Intellia Initiates BLA Submission for Lonvo-z in HAE Treatment
- BLA Submission Initiated: Intellia Therapeutics has begun the rolling submission of a Biologics License Application (BLA) to the FDA for lonvo-z, aimed at providing a one-time treatment for hereditary angioedema (HAE), which, if approved, would be the world's first CRISPR-based gene editing therapy.
- Clinical Trial Success: The Phase 3 HAELO trial of lonvo-z met its primary and all key secondary endpoints, demonstrating that most patients experienced freedom from HAE attacks and ongoing therapy needs during the six-month observation period, indicating its potential revolutionary impact on treatment.
- Expedited Review Pathway: With the FDA granting lonvo-z the Regenerative Medicine Advanced Therapy (RMAT) designation, Intellia can submit portions of the BLA on an ongoing basis, anticipating completion in the second half of 2026, and if approved, plans to commercially launch in the first half of 2027, significantly enhancing patient access to treatment.
- Regulatory Designations: Lonvo-z has received five notable regulatory designations, including Orphan Drug and RMAT designations from the FDA, highlighting its potential in treating HAE and the possibility of improving patients' quality of life while reducing reliance on long-term therapies.
See More
ARK Investment Management Increases NTLA Holdings
- Consistent NTLA Accumulation: ARK Investment Management has steadily increased its holdings in Intellia Therapeutics (NTLA) throughout 2026, acquiring over 263,848 shares from January to April, with a potential investment exceeding $3.5 million, reflecting a strong long-term confidence in the biotech firm.
- Positive Clinical Trial Results: Intellia recently reported positive Phase 3 trial results for lonvoculin ziclumeran (lonvo-z) for hereditary angioedema treatment and has initiated a rolling Biologics License Application submission to the FDA, aiming for a potential U.S. launch in the first half of 2027.
- Rocket Lab Stock Sale: ARK's second sale of Rocket Lab (RKLB) stock this month involved offloading 50,312 shares, potentially worth over $4 million, indicating a strategy to lock in gains after RKLB's impressive 262% rise over the past year.
- Retail Investor Sentiment: On Stocktwits, retail sentiment for NTLA is in the 'extremely bullish' territory, while RKLB is 'bullish', suggesting positive market expectations for both stocks, despite ARKK and ARKQ showing 'bearish' sentiment.
See More
Intellia Reports Positive Phase 3 Results for Lonvo-z in Hereditary Angioedema
- Clinical Trial Success: Intellia Therapeutics reported positive Phase 3 results from its global HAELO trial, demonstrating that a single dose of lonvoguran ziclumeran achieved an 87% reduction in swelling attacks, marking a significant milestone for gene-editing treatments.
- Significant Patient Response: Among 80 participants, those receiving lonvo-z had a mean monthly attack rate of 0.26 compared to 2.10 in the placebo group, showcasing a clear advantage in attack frequency reduction, with 62% of patients attack-free and off ongoing medication.
- Favorable Safety Profile: Lonvo-z was generally well tolerated, with all reported adverse events being mild or moderate, and no serious adverse events occurred, indicating a strong safety profile that supports future market adoption.
- Regulatory Progress: Intellia has initiated a rolling BLA submission to the FDA for lonvo-z, expected to be completed in the second half of 2026; if approved, it could become the first in vivo CRISPR-based therapy on the market, with a potential U.S. launch targeted for 2027.
See More
Intellia Therapeutics Launches $150M Public Offering
- Offering Announcement: Intellia Therapeutics has initiated a public offering of $150 million in common stock, aimed at funding future research and operations, thereby strengthening its market position in gene therapy.
- Underwriter Option: The company may grant underwriters a 30-day option to purchase an additional 15% of shares, a flexible financing strategy that will help meet market demand and optimize its capital structure.
- Clinical Progress: Following the FDA lifting the clinical hold on nex-z, Intellia's stock surged, reflecting market confidence in its product pipeline, particularly in the ATTR-CM space where potential breakthroughs are anticipated.
- Future Plans: Intellia is set to launch Lonvoguran Ziclumeran in 2026, and with ongoing clinical advancements, the company's market outlook in hereditary angioedema treatment is becoming increasingly promising.
See More
NASDAQ 100 Pre-Market Activity Overview
- Market Performance: The NASDAQ 100 Pre-Market Indicator is down 22.14 points to 27,281.53, indicating cautious market sentiment that may influence short-term investor decisions.
- Active Stocks: Organon & Co. (OGN) rises by $1.91 to $13.17 with a trading volume of 34,420,118 shares, currently priced at 146.33% of its target price, reflecting optimistic market expectations for its future performance.
- Earnings Forecast: Intel Corporation (INTC) has had three upward revisions in earnings forecasts over the past four weeks, with a current stock price of $82.86 and an expected EPS of $0.08 for the fiscal quarter ending June 2027, showcasing market confidence in its future profitability.
- Short Interest Data: Sagimet Biosciences Inc. (SGMT) and Intellia Therapeutics, Inc. (NTLA) have days to cover of 10.41 and 15.42 respectively, indicating high short-term trading activity for these stocks, which may impact their price volatility.
See More
Intellia Achieves Breakthrough in Rare Genetic Condition Treatment
- Clinical Trial Success: Intellia Therapeutics' lonvo-z demonstrated a remarkable efficacy in its Phase 3 trial, with 62% of patients completely free of HAE attacks over six months, compared to just 11% in the placebo group, indicating a potential paradigm shift in treatment for this rare genetic condition.
- FDA Application Initiated: The company has commenced a rolling Biologics License Application submission to the U.S. FDA, with plans for a potential U.S. launch of lonvo-z in the first half of 2027, which could open significant market opportunities and revenue streams for Intellia.
- Positive Market Reaction: Intellia's shares surged over 9% in pre-market trading on Monday, making it the top trending stock, reflecting strong investor optimism about lonvo-z, with a year-to-date increase of 52% in stock price.
- Significant Patient Impact: As a one-time treatment, lonvo-z aims to permanently reduce kallikrein and bradykinin levels through CRISPR gene editing, offering new hope for patients who have long suffered from HAE, potentially improving their quality of life significantly.
See More
